Day: March 5, 2021

Norsk Hydro: Invitasjon til Investorpresentasjon – Hydro selger forretningsområdet Rolling til KPS Capital Partners

Written by Customer Service on March 5, 2021. Posted in Public Companies.

Konsernsjef Hilde Merete Aasheim vil presentere transaksjonen i dag, fredag 5. mars kl. 09.00 (norsk tid) via audio webcast og telefonkonferanse.Presentasjonen kan følges via audio webcast. Det vil være mulig å stille spørsmål rett etter presentasjonen. For å stille spørsmål må du være koblet på telefonkonferansen før presentasjonen er ferdig. Se detaljer nedenfor. Det vil ikke være mulig å stille spørsmål via audio webcast.Du melder deg på telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start. Du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og koble deg til konferansen. “Click to Join“-lenken vil være aktiv fra 15 minutter før planlagt start.Vennligst bruk “Click to Join“ for den enkleste måten å delta på telefonkonferansen.Click to Join...

Annual Report 2020: The conglomerate shows its strength

Written by Customer Service on March 5, 2021. Posted in Public Companies.

The conglomerate shows its strength in 2020HighlightsRealised in 2020A highly unusual year with increased volume sales and a strong EBITDA improvement. Solid cash flows from operations and sharply reduced debt along with successful capitalisation of business opportunities.Revenue rose by 2% to DKK 21,273 million (2019: DKK 20,946 million)EBITDA rose by 13% to DKK 2,209 million (2019: DKK 1,951 million)Cash flow from operating activities improved by 63% to DKK 2,296 million (2019: DKK 1,410 million)ROIC excl. goodwill was 15.3 % (2019: 12.3%)Proposal that the dividend for the 2020 financial year remain at DKK 14 per share.Outlook for 2021Guidance for higher revenue and for EBITDA to remain high.Business activity is expected to remain at a high level, and increased investments to be made during the year will provide the basis for additional...

Årsrapport 2020: Konglomeratet viser sin styrke

Written by Customer Service on March 5, 2021. Posted in Public Companies.

Konglomeratet viser sin styrke i 2020HovedpunkterRealiseret i 2020Et helt usædvanligt år, der gav øget afsætning og stor fremgang i EBITDA. Solid pengestrøm fra drift og markant gældsnedbringelse samt succesfuld udnyttelse af opståede forretningsmuligheder.Omsætningen steg med 2% til 21.273 mio. kr. (2019: 20.946 mio. kr.)EBITDA steg med 13% til 2.209 mio. kr. (2019: 1.951 mio. kr.)Cash flow fra drift steg med 63% til 2.296 mio. kr. (2019: 1.410 mio. kr.)Afkastet af den investerede kapital (ROIC) ekskl. goodwill blev på 15,3% (2019: 12,3%)Udbyttet for regnskabsåret 2020 foreslås fastholdt på 14 kr. pr. aktie.Forventninger til 2021Forventning om øget omsætning og EBITDA på fortsat højt niveau.Aktiviteten forventes fastholdt på et højt niveau, og øgede investeringer i året vil danne basis for yderligere vækst. Coronavirus er stadig en del...

Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million

Written by Customer Service on March 5, 2021. Posted in Public Companies.

Energy and aluminium company Norsk Hydro ASA has entered into an agreement to sell its Rolling business to KPS Capital Partners for EUR 1,380 million on an enterprise value basis. A major step on Hydro’s agenda to improve profitability and drive sustainability.The transaction includes seven plants, one R&D center, global sales offices, and around 5,000 employees of which 650 employees in Norway and the remaining mainly in Germany.“Hydro launched a strategic review of our Rolling business area in 2019, along with other strategic measures towards profitability and sustainability. We have now concluded, and our Rolling business will continue its development under new ownership. This is a good solution for both Hydro and for the employees in Rolling, who will continue their efforts and continued growth in a new, dedicated downstream...

Polyphor Announces Financial Results for the Full-Year 2020

Written by Customer Service on March 5, 2021. Posted in Public Companies.

Phase III trial patient enrollment for balixafortide completed in Q4 2020 despite COVID-19. Results expected for ORR and PFS in Q2 and Q4 2021 respectivelyExclusive licensing agreement for balixafortide in China with Fosun PharmaClinical Trial Authorization (CTA) granted by MHRA to initiate Phase I trial for inhaled murepavadin. Patient enrollment expected in Q3 2021Grants for the antibiotics pipeline from CARB-X and CF Foundation enabling pipeline progression with non-dilutive financingResearch efforts for new CXCR4 lead candidate in hematologic malignancies and balixafortide in SARS-CoV-2 provide incremental pipeline expansion opportunityCash on hand of CHF 34.3 million as of December 31, 2020 is expected to finance operations into Q3 2021ALLSCHWIL, Switzerland, March 05, 2021 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) a research...

Audited Annual Report 2019 of EfTEN Real Estate Fund III AS

Written by Customer Service on March 5, 2021. Posted in Public Companies.

The management board of EfTEN Real Estate Fund III AS sent to the Supervisory Board for approval the 2020 audited annual report of EfTEN Real Estate Fund III AS. Financial results remained unchanged compared to the preliminary financial results published on 16th of February 2021.The consolidated sales revenue of EfTEN Real Estate Fund III AS for year 2020 was EUR 10.731 million, which increased by 12.8% in a year. The net profit of the same period was 3.317 million euros (2019: 7.737 thousand euros).The management board of EfTEN Real Estate Fund III AS proposes to the Supervisory Board and the General Meeting of Shareholders to pay a dividend of 66.3 cents per share, ie a total of EUR 2.798 million.The EfTEN Real Estate Fund III AS audited and consolidated Annual Report 2020 is attached to the announcement and is available on EfTEN Real...

EfTEN Real Estate Fund III AS 2020. aasta auditeeritud majandusaasta aruanne

Written by Customer Service on March 5, 2021. Posted in Public Companies.

EfTEN Real Estate Fund III AS-i juhatus esitas nõukogule heakskiitmiseks EfTEN Real Estate Fund III AS-i 2020. aasta auditeeritud majandustulemused. Auditeeritud aruandes ei ole kontserni finantstulemused võrreldes 16. veebruaril 2021 avaldatud esialgsete majandustulemustega muutunud.EfTEN Real Estate Fund III AS-i konsolideeritud 2020. aasta müügitulu oli 10,731 miljonit eurot, kasvades aastaga 12,8%. Kontserni puhaskasum samal perioodil oli 3,317 miljonit eurot (2019: 7,617 miljonit eurot). EfTEN Real Estate Fund III AS-i juhatus teeb nõukogule ja aktsionäride üldkoosolekule ettepaneku maksta dividende 66.3 eurosenti aktsia kohta, s.o kokku 2,798 miljonit eurot.EfTEN Real Estate Fund III AS-i konsolideeritud 2020. aasta konsolideeritud majandusaasta aruanne on lisatud teatele ning tehakse kättesaadavaks EfTEN Real Estate Fund III AS-i...

Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference

Written by Customer Service on March 5, 2021. Posted in Public Companies.

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:H.C. WAINWRIGHT Global Life Sciences 2021 (Virtual Conference)Sorrento’s Corporate Presentation will be available on-demand for 90 days starting on Tuesday, March 9, 2021 at 7:00 AM (Eastern Standard Time) at the following link:https://journey.ct.events/view/59a9d08e-a747-4170-a89e-fb9199cdf325An updated corporate presentation will also be available at www.sorrentotherapeutics.com.About Sorrento Therapeutics, Inc.Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is...

ObsEva Announces Year End 2020 Financial Results and Business Update

Written by Customer Service on March 5, 2021. Posted in Earnings Releases And Operating Results.

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21--Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21--Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept--Actively pursuing new indications and partnerships to maximize value of pipeline candidates- GENEVA, Switzerland and BOSTON, MA – March 5, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the year ended December 31, 2020 and provided a business update.“2020 was a critical year for ObsEva as it marked the beginning of our transformation from a clinical...

CGG: Announces its Q4 and Full Year 2020 Results

Written by Customer Service on March 5, 2021. Posted in Earnings Releases And Operating Results.

CGG Announces its Q4 and Full Year 2020 Results

Day: March 5, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals